drugset
drugset / Trial / NCT00169130

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

NCT00169130 ↗

Phase 2/3 Completed 300 enrolled Lymphoma Study Association Fondation ARC · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of the study is to evaluate the efficacy of ASCT as consolidation in case of bcl-2 overexpression in non previously treated patients aged 60 years or less with low-intermediate risk diffuse large B-cell lymphoma who responded to ACVBP regimen. Our goal is to obtain a 15% increase of event-free survival at 2 years.

Timeline

Start
1999-10
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclophosphamide Other / unclassified — —
Background Doxorubicin Other / unclassified — —

Indications

diffuse large B-cell lymphoma